DE69911620D1 - Muskarinische antagonisten zur behandlung von presbyopie - Google Patents

Muskarinische antagonisten zur behandlung von presbyopie

Info

Publication number
DE69911620D1
DE69911620D1 DE69911620T DE69911620T DE69911620D1 DE 69911620 D1 DE69911620 D1 DE 69911620D1 DE 69911620 T DE69911620 T DE 69911620T DE 69911620 T DE69911620 T DE 69911620T DE 69911620 D1 DE69911620 D1 DE 69911620D1
Authority
DE
Germany
Prior art keywords
treating presbyopia
muscarine antagonists
muscarine
antagonists
cholinergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69911620T
Other languages
English (en)
Other versions
DE69911620T2 (de
Inventor
Arlene Gwon
Mussie Elizabeth Wolde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69911620D1 publication Critical patent/DE69911620D1/de
Publication of DE69911620T2 publication Critical patent/DE69911620T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69911620T 1998-07-30 1999-07-22 Muskarinische antagonisten zur behandlung von presbyopie Expired - Fee Related DE69911620T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/126,064 US6291466B1 (en) 1998-07-30 1998-07-30 Cholinergic agents in the treatment of presbyopia
US126064 1998-07-30
PCT/US1999/016260 WO2000006135A2 (en) 1998-07-30 1999-07-22 Cholinergic agents in the treatment of presbyopia

Publications (2)

Publication Number Publication Date
DE69911620D1 true DE69911620D1 (de) 2003-10-30
DE69911620T2 DE69911620T2 (de) 2004-07-29

Family

ID=22422802

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911620T Expired - Fee Related DE69911620T2 (de) 1998-07-30 1999-07-22 Muskarinische antagonisten zur behandlung von presbyopie

Country Status (13)

Country Link
US (2) US6291466B1 (de)
EP (1) EP1100480B1 (de)
JP (1) JP2002521429A (de)
KR (1) KR20010079593A (de)
CN (1) CN1157186C (de)
AT (1) ATE250412T1 (de)
AU (1) AU754588B2 (de)
BR (1) BR9912599A (de)
CA (1) CA2339093A1 (de)
DE (1) DE69911620T2 (de)
ES (1) ES2207963T3 (de)
HK (1) HK1035493A1 (de)
WO (1) WO2000006135A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
AU2007272963B2 (en) 2006-07-11 2013-05-23 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
GB0711151D0 (en) * 2007-06-11 2007-07-18 Sra Dev Ltd Switch for use with an ultrasonic surgical tool
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2512492A1 (de) * 2009-12-14 2012-10-24 University of Massachusetts Verfahren zur hemmung von grauem star und altersweitsichtigkeit
US8889735B2 (en) * 2011-04-07 2014-11-18 Sucampo Ag Method for treating asthenopia
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
EA029070B1 (ru) 2013-03-14 2018-02-28 Дзе Юниверсити Оф Массачусетс Способ задержки развития катаракты и пресбиопии
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US20170007637A1 (en) * 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
MX2017016518A (es) 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
US10736863B2 (en) 2015-11-13 2020-08-11 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
WO2019097318A1 (en) * 2017-11-17 2019-05-23 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
EP3681500B1 (de) * 2018-04-24 2022-03-23 Allergan, Inc. Verwendung von pilocarpinhydrochlorid zur behandlung von presbyopie
EP3860600A4 (de) * 2018-10-06 2022-07-20 Biotheravision, Inc Ophthalmische zubereitungen eines muscarinagonisten und verwendungsverfahren
CN110496215A (zh) * 2019-08-23 2019-11-26 中国人民解放军总医院 一种治疗老视的水性滴眼液及其制备方法
KR20230042077A (ko) * 2020-09-11 2023-03-27 인트라투스-네바다, 인크. 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
MX2023004276A (es) * 2020-10-14 2023-05-02 Santen Pharmaceutical Co Ltd Composicion farmaceutica estable.
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US20230263727A1 (en) 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
WO2023190653A1 (ja) * 2022-03-30 2023-10-05 参天製薬株式会社 医薬製剤の滅菌法と包装体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
ATE203666T1 (de) 1989-06-21 2001-08-15 Univ Pennsylvania Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
AU4653993A (en) 1992-07-02 1994-01-31 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia

Also Published As

Publication number Publication date
AU754588B2 (en) 2002-11-21
WO2000006135A3 (en) 2000-03-23
AU5216099A (en) 2000-02-21
US6291466B1 (en) 2001-09-18
ATE250412T1 (de) 2003-10-15
WO2000006135A2 (en) 2000-02-10
US6410544B1 (en) 2002-06-25
HK1035493A1 (en) 2001-11-30
CA2339093A1 (en) 2000-02-10
DE69911620T2 (de) 2004-07-29
CN1157186C (zh) 2004-07-14
ES2207963T3 (es) 2004-06-01
EP1100480B1 (de) 2003-09-24
JP2002521429A (ja) 2002-07-16
BR9912599A (pt) 2001-05-02
KR20010079593A (ko) 2001-08-22
EP1100480A2 (de) 2001-05-23
CN1311670A (zh) 2001-09-05

Similar Documents

Publication Publication Date Title
DE69911620D1 (de) Muskarinische antagonisten zur behandlung von presbyopie
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE361752T1 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
BR0007699A (pt) Métodos para restaurar e/ou melhorar a acomodação de pseudofaquia
ATE459335T1 (de) Verfahren zur behandlung von augenerkrankungen
ATE328588T1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NZ334063A (en) use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
ATE304886T1 (de) Oxazolidinones zur behandlung von augeninfektionen
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE69721747D1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE252911T1 (de) Behandlung von störungen mittels interleukin-9
DE69524388D1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
FI963220A (fi) 5-substituoidun mykofenolihapon 4-aminojohdannaiset
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee